Plasma-based signatures have predicted response and survival in triple-negative breast cancer, with immune and antigen-presentation modules enriched among top features (11), and multiplex plasma panels in non–small cell lung cancer (NSCLC) have similarly captured host-tumor crosstalk beyond tissue PD-L1, improving discrimination of clinical outcomes (14). Here, CD274 is linked to lung cancer.